Application of 3D-QSAR techniques in anti-HIV-1 drug design - An overview

Current Pharmaceutical Design

Volumn 11, Issue 24, 2005, Pages 3091-3110

  Debnath, Asim Kumar ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

3D QSAR; Binding free energy; Catalyst HypoGen; CCR5; CoMFA; CoMSIA; CXCR4; GOLPE; gp120; gp41; GRID; HASL; HINT; HIV 1; Integrase; Pharmacophore; Protease; Reverse transcriptase; VolSurf

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYCLOHEXANONE DERIVATIVE; FLAVONE DERIVATIVE; GLYCOPROTEIN GP 120; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INTEGRASE; INTEGRASE INHIBITOR; MERCAPTOBENZENESULFONAMIDE DERIVATIVE; NEVIRAPINE; NSC 119833; PHTHALIMIDE DERIVATIVE; PORPHYRIN DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR; QUINOLONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SDZ 282870; STYRYLQUINOLINE DERIVATIVE; TETRAHYDROIMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINONE; THIAZOLOTHIAZEPINE DERIVATIVE; UK 129485; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BINDING AFFINITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; IC 50; MOLECULAR MECHANICS; NONHUMAN; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 23844477186     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054864902     Document Type: Review

References (110)

1. AIDS epidemic update December 2004; UNAIDS: Geneva Switzerland 2004.
2. Weitzel T, Plettenberg A, Albrecht D, Lorenzen T, Stoehr A. Severe anemia as a newly recognized side-effect caused by lamivudine. AIDS 1999; 13: 2309-2311.
3. Fortuny C, Vicente MA, Medina MM, Gonzalez-Ensenat A. Rash as side-effect of nelfinavir in children. AIDS 2000; 14: 335-336.
4. Das SJ, Olsen I. Keratinocyte growth factor is upregulated by the hyperplasia-inducing drug nifedipine. Cytokine 2000; 12: 1566-1569.
5. Savini CJ, James CW, Miller JL, Wilson SA, Cohen DM, Perlada DE. Evidence of hypertriglyceridemia in managing HIV patients on efavirenz. J Assoc Nurses AIDS Care 2001; 12: 95-97.
6. Foli A, Benvenuto F, Piccinini G, Bareggi A, Cossarizza A, Lisziewicz J, Lori F. Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 2001; 15: 1687-1694.
7. Ahlsen G, Hulten J, Shuman CF, Poliakov A, Lindgren MT, Alterman M, Samuelsson B, Hallberg A, Danielson UH. Resistance profiles of cyclic and linear inhibitors of HIV-1 protease. Antivir Chem Chemother 2002; 13: 27-37.
8. Blaise P, Clevenbergh P, Vaira D, Moutschen M, Dellamonica P. HIV resistance to antiretroviral drugs: mechanisms genotypic and phenotypic resistance testing in clinical practice. Acta Clin Belg 2002; 57: 191-201.
9. Kuritzkes DR. Resistance to protease inhibitors. J HIV Ther 2002; 7: 87-91.
10. Hansch C, Leo A. Exploring QSAR Fundamentals and applications in chemistry and biology; American Chemical Society: Washington DC 1995; Vol. 1.
11. Hansch C, Leo A, Hoekman D. Exploring QSAR Volume 2: Hydrophobic electronic and steric constants; American Chemical Society: 1995; Vol. 2.
12. Debnath AK. Quantitative structure-activity relationship (QSAR) paradigm - Hansch era to new millennium. Mini Rev Med Chem 2001; 1: 187-195.
13. Kellogg GE, Semus SF. 3D QSAR in modern drug design. EXS 2003; 223-241.
14. Mason JS, Good AC, Martin EJ. 3-D pharmacophores in drug discovery. Curr Pharm Des 2001; 7: 567-597.
15. Podlogar BL, Ferguson DM. QSAR and CoMFA: a perspective on the practical application to drug discovery. Drug Des Discov 2000; 17: 4-12.
16. Selassie CD, Mekapati SB, Verma RP. QSAR: then and now. Curr Top Med Chem 2002; 2: 1357-1379.
17. Wlodawer A. Structure-based design of AIDS drugs and the development of resistance. Vox Sang 2002; 83 (Suppl 1): 23-26.
18. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27: 249-284.
19. Hardy LW, Malikayil A. Impact of structure-guided drug design on clinical agents. Curr Drug Discov 2003; 15.
20. Garg R, Gupta SP, Gao H, Babu MS, Debnath AK, Hansch C. Comparative Quantitative Structure-Activity Relationship Studies on Anti-HIV Drugs. Chemical Reviews 1999; 99: 3525-3602.
21. Gupta SP. Advances in QSAR studies of HIV-1 reverse transcriptase inhibitors. Prog Drug Res 2002; 58: 223-264.
22. Kurup A, Mekapati SB, Garg R, Hansch C. HIV-1 protease inhibitors: a comparative QSAR analysis. Curr Med Chem 2003; 10: 1679-1688.
23. Ivanoff LA, Looney DJ, McDanal C, Morris JF, Wong-Staal F, Langlois A, Petteway SR Jr, Matthews TJ. Alteration of HIV-1 infectivity and neturalization by a single amino acid replacement in the V3 loop domain. AIDS Res Hum Retrov 1991; 7: 595-603.
24. Page KA, Stearns SM, Littman DR. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity. J Virol 1992; 66: 524-533.
25. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, Matthews TJ. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989; 86: 6768-6772.
26. Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, Haynes BF. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988; 85: 1932-1936.
27. Catasti P, Fontenot JD, Bradbury EM, Gupta G. Local and global structural properties of the HIV-MN V3 loop. J Biol Chem 1995; 270: 2224-2232.
28. Neurath AR, Strick N, Haberfield P, Jiang S. Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. II. Porphyrins reacting with the V3 loop of gp120. Antiviral Chem Chemother 1992; 3: 55-63.
29. Neurath AR, Strick N, Jiang S. Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. Approaches applicable to epidemic HIV-1 strains. Antiviral Chem Chemother 1993; 4: 207-214.
30. Debnath AK, Jiang S, Strick N, Lin K, Haberfield P, Neurath AR. Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. J Med Chem 1994; 37: 1099-1108.
31. Marshall GR, Barry CD, Bosshard HE, Dammkoehler RA, Dunn DA. The conformational parameter in drug design: The active analog approach in Computer-Assisted Drug Design Olson EC, Christoffersen RE. editors; American Chemical Society: Washington DC 1979; Chapter 9 pp. 205-226.
32. Mayer D, Naylor CB, Motoc I, Marshall GR. A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies. J Comput Aid Mol Des 1987; 1: 3-16.
33. Joao HC, de Vreese K, Pauwels R, De Clercq E, Henson GW, Bridger GJ. Quantitative structure activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J Med Chem 1995; 38: 3865-3873.
34. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2: 581-587.
35. Debnath AK. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. J Med Chem 2003; 46: 4501-4515.
36. Li H, Sutter J, Hoffman R. HypoGen: An automated system for generating 3D predictive pharmacophore models in Pharmacophore Perception Development and Use in Drug Design Guner OF. editor; International University Line: La Jolla CA 1999; Chapter 10: pp. 173-189.
37. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: A Program for Macromolecular Energy Minimization and Dynamics Calculations. J Comput Chem 1983; 4: 187-212.
38. Song M, Breneman CM, Sukumar N. Three-dimensional quantitative structure-activity relationship analyses of piperidine-based CCR5 receptor antagonists. Bioorg Med Chem 2004; 12: 489-499.
39. Clark M, Cramer RD. III; Van Opdenbosch N. Validation of the general purpose Tripos 5.2 force field. J Comput Chem 1989; 10: 982-1012.
40. Hannongbua S, Lawtrakul L, Sotriffer CA, Rode BM. Comparative Molecular Field Analysis of HIV-1 Reverse Transcriptase Inhibitors in the Class if 1[(2-Hydroxyethoxy)-methyl]-6-(phenylthio)thymine. Quant Struct-Act Rel 1996; 15: 389-394.
41. Kireev DB, Chretien JR, Grierson DS, Monneret C. A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition. J Med Chem 1997; 40: 4257-4264.
42. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP. AM1: A new general purpose quantum mechanical molecular model. J Am Chem Soc 1985; 107: 3902-3909.
43. Clementi S, Wold S. How to choose the proper statistical method. Section 5.2.6 Conclusions. in Chemometric methods in drug design van de Waterbeemd H. editor; VCH: Weinheim 1995; pp. 319-338.
44. Hannongbua S, Nivesanond K, Lawtrakul L, Pungpo P, Wolschann P. 3D-quantitative structure-activity relationships of HEPT derivatives as HIV-1 reverse transcriptase inhibitors based on Ab initio calculations. J Chem Inf Comput Sci 2001; 41: 848-855.
45. Hannongbua S, Pungpo P, Limtrakul J, Wolschann P. Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors. J Comput Aid Mol Des 1999; 13: 563-577.
46. Chen HF, Yao XJ, Li Q, Yuan SG, Panaye A, Doucet JP, Fan BT. Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking. SAR QSAR Environ Res 2003; 14: 455-474.
47. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 1996; 10: 293-304.
48. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 1996; 9: 1-5.
49. Gussio R, Pattabiraman N, Zaharevitz DW, Kellogg GE, Topol IA, Rice WG, Schaeffer CA, Erickson JW, Burt SK. All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach. J Med Chem 1996; 39: 1645-1650.
50. Andzelm J, Wimmer E. DGauss - a density functional method for molecular and electronic structure calculations in the 1990s. Physica B: Condensed Matter 1991; 172: 307-317.
51. Gussio R, Pattabiraman N, Kellogg GE, Zaharevitz DW. Use of 3D QSAR methodology for data mining the National Cancer Institute Repository of Small Molecules: application to HIV-1 reverse transcriptase inhibition. Methods 1998; 14: 255-263.
52. Pungpo P, Hannongbua S. Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives using comparative molecular field analysis. J Mol Graph Model 2000; 18: 581-90 601.
53. Cruciani G, Pastor M, Guba W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 2000; 11 Suppl 2: S29-S39.
54. Filipponi E, Cruciani G, Tabarrini O, Cecchetti V, Fravolini A. QSAR study and VolSurf characterization of anti-HIV quinolone library. J Comput Aid Mol Des 2001; 15: 203-217.
55. Samee W, Ungwitayatom J, Matayatsuk C, Pimthon J. 3D-QSAR studies on phthalimide derivatives as HIV-1 reverse transcriptase inhibitors. ScienceAsia 2004; 30: 81-88.
56. Waller CL, Oprea TI, Giolitti A, Marshall GR. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. J Med Chem 1993; 36: 4152-4160.
57. Doweyko AM. Three-dimensional pharmacophores from binding data. J Med Chem 1994; 37: 1769-1778.
58. Kroemer RT, Ettmayer P, Hecht P. 3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors: comparative molecular field analysis of 2-heterosubstituted statine derivatives-implications for the design of novel inhibitors. J Med Chem 1995; 38: 4917-4928.
59. Holloway MK, Wai JM, Halgren TA, Fitzgerald PM, Vacca JP, Dorsey BD, Levin RB, Thompson WJ, Chen LJ, deSolms SJ. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J Med Chem 1995; 38: 305-317.
60. Gund P, Andose JD, Rhodes JB, Smith GM. Three-dimensional molecular modeling and drug design. Science 1980; 208: 1425-1431.
61. Viswanadhan VN, Reddy MR, Wlodawer A, Varney MD, Weinstein JN. An approach to rapid estimation of relative binding affinities of enzyme inhibitors: application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease. J Med Chem 1996; 39: 705-712.
62. Viswanadhan VN, Ghose AK, Revankar GR, Robins RK. Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships IV. Additional parameters for hydrophobic and dispersive interactions and their application for and automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 1989; 29: 163-172.
63. Oprea TI, Waller CL, Marshall GR. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results. Drug Des Discov 1994; 12: 29-51.
64. Jenwitheesuk E, Samudrala R. Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations. BMC Struct Biol 2003; 3: 2.
65. Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, Phillips J, Shinozaki A, Varadarajan K, Schulten K. NAMD2: Greater scability for parallel molecular dynamics. J Comput phys 1999; 151: 283-312.
66. Brunger AT. X-Plor version 3.1 A system for X-ray crystallography and NMR. Yale University Press: New Haven CT 1992.
67. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using Lamarckian genetic algoritm and empirical binding free energy function. J Comput Chem 1998; 19: 1639-1662.
68. Zoete V, Michielin O, Karplus M. Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors. J Comput Aid Mol Des 2003; 17: 861-880.
69. Ortiz AR, Pisabarro MT, Gago F, Wade RC. Prediction of drug binding affinities by comparative binding energy analysis. J Med Chem 1995; 38: 2681-2691.
70. Perez C, Pastor M, Ortiz AR, Gago F. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. J Med Chem 1998; 41: 836-852.
71. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, Ferguson DM, Seibel GL, Sing UC, Weiner P, Kollman PA. AMBER(UCSF): Assisted model building with energy refinement. Department of Pharmaceutical Chemistry University of California San Francisco 1995.
72. Pastor M, Perez C, Gago F. Simulation of alternative binding modes in a structure-based QSAR study of HIV-1 protease inhibitors. J Mol Graph Model 1997; 15: 364-71.
73. Nicholls A, Honig B. A rapid finite difference algorithm utilizing successive over-relaxation to solve the Poisson-Boltzmann equation. J Comput Chem 1991; 12: 445.
74. Pastor M. GOLPE Multivariate Infometric Analysis (MIA). Perugia Italy 1996.
75. Kulkarni SS, Kulkarni VM. Structure based prediction of binding affinity of human immunodeficiency virus-1 protease inhibitors. J Chem Inf Comput Sci 1999; 39: 1128-1140.
76. Debnath AK. Comparative molecular field analysis (CoMFA) of a series of symmetrical bis-benzamide cyclic urea derivatives as HIV-1 protease inhibitors. J Chem Inf Comput Sci 1998; 38: 761-767.
77. Debnath AK. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis (CoMFA). J Med Chem 1999; 42: 249-259.
78. Kellogg GE, Semus SF, Abraham DJ. HINT: a new method of empirical hydrophobic field calculation for CoMFA. J Comput Aid Mol Des 1991; 5: 545-552.
79. Jayatilleke PR, Nair AC, Zauhar R, Welsh WJ. Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. J Med Chem 2000; 43: 4446-4451.
80. Norinder U. Refinement of Catalyst hypotheses using simplex optimisation. J Comput Aid Mol Des 2000; 14: 545-557.
81. Schaal W, Karlsson A, Ahlsen G, Lindberg J, Andersson HO, Danielson UH, Classon B, Unge T, Samuelsson B, Hulten J, Hallberg A, Karlen A. Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors. J Med Chem 2001; 44: 155-169.
82. McDonald DQ, Still WC. AMBER* torsional parameters for the peptide backbone. Tetrahedron Lett 1992; 33: 7743-7746.
83. Still WC, Tempczyk A, Hawley RC, hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 1990; 112: 6127-6129.
84. Mohamadi F, Richards NG. J, Guida WC, Liskamp R, Lipton M, Caufield C, Chang G, hendrickson T, Still WC. Macromodel - An integrated software system for molecular modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 1990; 11: 440-467.
85. Bush BL, Nachbar RB Jr. Sample-distance partial least squares: PLS optimized for many variables with application to CoMFA. J Comput Aid Mol Des 1993; 7: 587-619.
86. Di Santo R, Costi R, Artico M, Massa S, Ragno R, Marshall GR, La Colla P. Design synthesis and QSAR studies on N-aryl heteroarylisopropanolamines a new class of non-peptidic HIV-1 protease inhibitors. Bioorg Med Chem 2002; 10: 2511-2526.
87. Huang X, Xu L, Luo X, Fan K, Ji R, Pei G, Chen K, Jiang H. Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models. J Med Chem 2002; 45: 333-343.
88. Nair AC, Jayatilleke P, Wang X, Miertus S, Welsh WJ. Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties. J Med Chem 2002; 45: 973-983.
89. Avram S, Svab I, Bologa C, Flonta ML. Correlation between the predicted and the observed biological activity of the symmetric and nonsymmetric cyclic urea derivatives used as HIV-1 protease inhibitors. A 3D-QSAR-CoMFA method for new antiviral drug design. J Cell Mol Med 2003; 7: 287-296.
90. Ungwitayatorn J, Samee W, Pimthon J. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors. J Mol Struct 2004; 689: 99-106.
91. Tervo AJ, Nyronen TH, Ronkko T, Poso A. Comparing the quality and predictiveness between 3D QSAR models obtained from manual and automated alignment. J Chem Inf Comput Sci 2004; 44: 807-816.
92. Broyden C. The convergence of a class of double-rank minimization algorithms. J Inst Math Appl 1970; 6(76): 222-90 231.
93. Flethcer R. A new approach to variable metric algorithm. Comput J 1970; 13: 317-322.
94. Goldfarb D. A family of variable-metric methods derived by variational means. Math Comput 1970; 24: 23-26.
95. Shanno D. Conditioning of Quasi-Newton methods for function minimization. Math Comput 1970; 24: 647-656.
96. Halgren AT. MMFF VI: MMFF94s option for energy minimization studies. J Comput Chem 1999; 20: 720-729.
97. Halgren TA. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J Comput Chem 1996; 17: 520-552.
98. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727-748.
99. Raghavan K, Buolamwini JK, Fesen MR, Pommier Y, Kohn KW, Weinstein JN. Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. J Med Chem 1995; 38: 890-897.
100. Makhija MT, Kulkarni VM. Molecular electrostatic potentials as input for the alignment of HIV-1 integrase inhibitors in 3D QSAR. J Comput Aid Mol Des 2001; 15: 961-978.
101. Makhija MT, Kulkarni VM. 3D-QSAR and molecular modeling of HIV-1 integrase inhibitors. J Comput Aid Mol Des 2002; 16: 181-200.
102. Buolamwini JK, Assefa H. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J Med Chem 2002; 45: 841-852.
103. Ma XH, Zhang XY, Tan JJ, Chen WZ, Wang CX. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies. Acta Pharmacol Sin 2004; 25: 950-958.
104. Baroni M, Constantino G, Cruciani G, Valigi R, Clemnti S. Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D-QSAR Problems. Quant Struct-Act Rel 1993; 12: 9-20.
105. Costi R, Santo RD, Artico M, Massa S, Ragno R, Loddo R, La Colla M, Tramontano E, La Colla P, Pani A. 2, 6-Bis(3, 4, 5-trihydroxybenzylydene) derivatives of cyclohexanone novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. Bioorg Med Chem 2004; 12: 199-215.
106. Kuo CL, Assefa H, Kamath S, Brzozowski Z, Slawinski J, Saczewski F, Buolamwini JK, Neamati N. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. J Med Chem 2004; 47: 385-399.
107. Mustata GI, Brigo A, Briggs JM. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors. Bioorg Med Chem Lett 2004; 14: 1447-1454.
108. Douali L, Villemin D, Cherqaoui D. Comparative QSAR based on neural networks for the anti-HIV activity of HEPT derivatives. Curr Pharm Design 2003; 9(22): 1817-26.
109. Ren SS, Lien EJ. Anticancer agents: tumor cell growth inhibitory activity and binary QSAR analysis. Curr Pharm Design 2004; 10(12): 1399-415.
110. van Drie JH. Pharmacophore discovery - lessons learned. Curr Pharm Design 2003; 9(20): 1649-64.